Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Trial Identifier: 3475-204
Sponsor: MSD
Start Date: May 2016
Primary Completion Date: July 2025
Study Completion Date: July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary-English

Trial Locations

No locations posted.